By Gali Halevi, MLS, PhD and Robin Milford, MSIS

Academic and corporate collaborations are vital to the development of drugs, medical equipment and various therapeutic procedures. In this article we explored the main corporations with which ISMMS collaborates with. Using Scopus, we retrieved all publications that have at least one ISMMS author and at least one corporate author from 2010 to 2015. Overall, we analyzed 585 co-authored publications. Our results show that ISMMS collaborated with 83 corporations worldwide between 2010 and 2015.

As can be seen in table 1, most of the co-authored papers are between North American and European corporations and ISMMS authors. However, there are several collaborations between Asian and Middle Eastern corporations.

Region totals Collaborating Institutions Co-authored publications
Asia Pacific 9 17
Europe 24 160
Middle East 3 6
North America 47 435

Table 1: Regional collaborations between corporations and ISMMS authors

North American collaborations show 435 co-authored papers with 47 corporations. The top co-authored papers are between Merck, Pfizer, Eli Lilly, Abbott Laboratories, SAIC and Bristol-Myers Squibb (see figure 1).

Graph 1: Corporate collaborations between ISMMS and American Corporations

An analysis of the titles of these co-authored publications reveals the main areas in which the collaborations took place which are HPV vaccine (Merck), overactive bladder control (Pfizer), Alzheimer Disease (Eli Lilly), Coronary Disease (Abbott Laboratories) and anti -rejection Kidney Transplant (Bristol-Myers Squibb)

European collaborations show 160 co-authored papers with 24 corporations.  The main corporations and areas of collaborative research are GlaxoSmithKline (HPV vaccine), Novartis (H1N1 vaccine), Sanofi-Aventis (Chemoradiography) and Bayer (hepatocellular carcinoma).

Graph 2: Corporate collaborations between ISMMS and Asian Corporations